- Fellowship - UT Southwestern Medical Center (1994-1997), Molecular Genetics
- Fellowship - UT Southwestern Medical Center (1991-1994), Gastroenterology
- Internship/Residency - Parkland Health & Hospital System (1988-1991), Internal Medicine
- Medical School - University of Iowa Hospitals and Clinics
Jay Horton, M.D.
- Center for Human Nutrition Director's Endowed Chair
- Scott Grundy Director's Chair
- The Dr. Robert C. and Veronica Atkins Chair in Obesity & Diabetes Research
- Distinguished Chair in Human Nutrition
- Internal Medicine - Digestive & Liver Diseases
Jay D. Horton obtained his B.S. and M.D. degrees from the University of Iowa in 1984 and 1988, respectively. He completed his internal medicine residency (1988-1991) and gastroenterology fellowship (1991-1994) at UT Southwestern Medical Center. During his gastroenterology fellowship he studied metabolic regulators of bile acid and cholesterol homeostasis in animals. Following the gastroenterology fellowship, he completed a Howard Hughes post doctoral fellowship in the Department of Molecular Genetics at UT Southwestern Medical Center. The studies in this fellowship focused on the transcriptional regulation of cholesterol and fatty acid synthesis.
In clinical digestive diseases, Dr. Horton has an interest in conditions that lead to steatosis and obesity. Currently the laboratory is investigating molecular mediators of steatosis using various mouse models. Investigations from the laboratory have revealed how the primary transcriptional regulators of cholesterol metabolism (sterol regulatory element-binding proteins) are also key regulators of fatty acid synthesis in liver.
A major focus of the laboratory is to determine how these transcriptional regulators contribute to the development of steatosis in various disease processes such as diabetes, obesity, and beta-oxidation defects.
A second area of investigation centers on determining the function of PCSK9, a protein that is involved in determining plasma LDL cholesterol levels through its ability to post-transcriptionally regulate the expression of the LDL receptor in liver.
- American Association of Clinical Endocrinologists Frontiers in Science Award 2016
- Research Scholar Award 1999, American Digestive Health Foundation
- PEW Scholar 2000, PEW Foundation
- Established Investigator 2000, American Heart Foundation
- American Society for Clinical Investigation 2003
- Association of American Physicians 2008
Hepatic gluconeogenesis is enhanced by phosphatidic Acid which remains uninhibited by insulin in lipodystrophic agpat2-/- mice.
Sankella S, Garg A, Horton JD, Agarwal AK The Journal of biological chemistry 2014 Feb 289 8 4762-77
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, Nochur SV, Kotelianski V, Horton J, Mant T, Chiesa J, Ritter J, Munisamy M, Vaishnaw AK, Gollob JA, Simon A Lancet 2014 Jan 383 9911 60-8
Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.
Berger JM, Loza Valdes A, Gromada J, Anderson N, Horton JD Journal of lipid research 2017 Jun
Expression of SREBP-1c requires SREBP-2-mediated generation of a sterol ligand for LXR in livers of mice.
Rong S, Cortés VA, Rashid S, Anderson NN, McDonald JG, Liang G, Moon YA, Hammer RE, Horton JD eLife 2017 Feb 6
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A The New England journal of medicine 2016 Nov
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Kim CW, Addy C, Kusunoki J, Anderson NN, Deja S, Fu X, Burgess SC, Li C, Ruddy M, Chakravarthy M, Previs S, Milstein S, Fitzgerald K, Kelley DE, Horton JD Cell metabolism 2017 Aug 26 2 394-406.e6
AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue.
Cautivo KM, Lizama CO, Tapia PJ, Agarwal AK, Garg A, Horton JD, Cortés VA Molecular metabolism 2016 Jul 5 7 491-505
A HFD suppresses de novo lipogenesis and desaturation, but not elongation and triglyceride synthesis in mice.
Duarte JA, Carvalho F, Pearson M, Horton JD, Browning JD, Jones JG, Burgess SC Journal of lipid research 2014 Sep
Deletion of ELOVL6 Blocks the Synthesis of Oleic Acid but does not Prevent the Development of Fatty Liver or Insulin Resistance.
Moon YA, Ochoa CR, Mitsche MA, Hammer RE, Horton JD Journal of lipid research 2014 Oct
Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin receptors.
Cortés VA, Cautivo KM, Rong S, Garg A, Horton JD, Agarwal AK Journal of lipid research 2014 Feb 55 2 276-88
An acetate switch regulates stress erythropoiesis.
Xu M, Nagati JS, Xie J, Li J, Walters H, Moon YA, Gerard RD, Huang CL, Comerford SA, Hammer RE, Horton JD, Chen R, Garcia JA Nature medicine 2014 Aug
- Hepatic gluconeogenesis is enhanced by phosphatidic Acid which remains uninhibited by insulin in lipodystrophic agpat2-/- mice.
- Lipid metabolism
- Hepatic steatosis